Drug Profile
Adalimumab biosimilar - Fujifilm Kyowa Kirin Biologics
Alternative Names: FKB-327; HulioLatest Information Update: 03 Aug 2023
Price :
$50
*
At a glance
- Originator FUJIFILM Corporation - Kyowa Hakko Kirin (JV); Fujifilm Kyowa Kirin Biologics
- Developer Biocon; Fujifilm Kyowa Kirin Biologics; Viatris Inc
- Class Anti-inflammatories; Anti-TNF monoclonal antibodies; Antineoplastics; Antipsoriatics; Antirheumatics; Eye disorder therapies; Hepatoprotectants; Immunotherapies; Monoclonal antibodies; Nootropics; Skin disorder therapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Immunosuppressants; Tumour necrosis factor alpha inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Ankylosing spondylitis; Axial spondyloarthritis; Behcet's syndrome; Crohn's disease; Hidradenitis suppurativa; Juvenile rheumatoid arthritis; Plaque psoriasis; Psoriasis; Psoriatic arthritis; Pustular psoriasis; Rheumatoid arthritis; Ulcerative colitis; Uveitis
Most Recent Events
- 03 Aug 2023 Launched for Ankylosing spondylitis (In adults) in Germany, Finland, Ireland, Switzerland, Sweden, Portugal, Poland, Netherlands, Austria, Spain, Czech Republic (SC) (Biocon website, August 2023)
- 03 Aug 2023 Launched for Axial spondyloarthritis (In adults) in France, Germany, Sweden, Netherlands, Poland, Austria, Canada, Spain, Czech Republic (SC) (Biocon website, August 2023)
- 03 Aug 2023 Launched for Crohn's disease (In adolescents, In children, In adults) in Germany, Switzerland, Sweden, Poland, Austria, Spain (SC) (Biocon website, August 2023)